FOXO4-DRI
Summary
FOXO4-DRI is an experimental senolytic peptide designed to disrupt the FOXO4–p53 interaction and induce apoptosis in senescent cells. Evidence includes human cell cultures and mouse experiments, with both beneficial findings and a pulmonary-hypertension warning signal. Searches of ClinicalTrials.gov and PubMed on October 14, 2026 did not identify a human treatment trial; human safety and an effective dose remain unestablished.
Also known as: FOXO4 D-Retro-Inverso, Proxofim
Key Findings at a Glance
- • The original FOXO4-DRI construct has 46 D-amino-acid residues including its cell-penetrating segment (Baar 2017).
- • The original mouse protocols used three alternate-day injections; follow-up weeks later is not continuous dosing or a half-life measurement.
- • Evidence includes human cell cultures and several mouse models; it does not establish a human anti-aging benefit.
- • A mouse pulmonary-hypertension study reported harm, so tolerability in the original aging models cannot establish general safety.
FOXO4-DRI Overview & Molecular Profile
FOXO4-DRI was introduced by Baar et al. in Cell (2017) as a senolytic peptide targeting the FOXO4–p53 interaction. The original construct contains 46 D-amino-acid residues, including its HIV-TAT-derived cell-penetrating segment. The study combined human fibroblast experiments with chemotherapy, accelerated-aging and naturally aged mouse models. Later studies include expanded human chondrocytes, keloid fibroblasts, endothelial cells and additional mouse disease models. Activity in human cells outside the body is not evidence of safety or efficacy in a person.
Mechanism of Action: Cellular Health & Telomere Research
In the original senescent-cell models, FOXO4-DRI interfered with FOXO4–p53 binding, promoted p53 exclusion from the nucleus and induced caspase-dependent apoptosis. The D-retro-inverso design uses a reversed sequence of D-amino acids and was intended to improve resistance to proteolysis. Selectivity was demonstrated under particular culture conditions; it does not establish that every non-senescent cell or tissue will be spared.
FOXO4-DRI Pharmacokinetics: What Remains Unknown
The original methods report a 46-residue D-isoform construct with a molecular weight of 5358.2 Da. Protease-resistant design and sustained biological effects do not establish plasma elimination half-life. The primary studies reviewed here do not establish human half-life, clearance or bioavailability.
Cellular Detection Is Not Plasma Half-Life
- • Baar et al. detected a TAT-associated signal in cultured senescent cells for at least 72 hours. This is an intracellular observation, not a plasma concentration–time study (PMID 28340339).
- • No measured human elimination half-life was identified in the October 14, 2026 PubMed search. A dosing interval cannot substitute for a measured exposure curve.
Mouse Dosing and Follow-Up
- • The original study reported 5 mg/kg on three alternate days (days 1, 3 and 5): intravenous administration in the doxorubicin experiment and intraperitoneal administration in specified aging experiments. Later outcome measurements, including renal markers at 30 days, do not mean dosing continued for weeks (PMID 28340339).
- • Later regimens differ. Hu et al. report 5 mg/kg intraperitoneally every two days for a month in naturally aged mice and for four weeks in a D-galactose model (PMID 41625068). Neither regimen establishes a human dose or duration of circulating drug.
Research-Observed Effects
Senolytic Activity in Cell Models
Preliminary ResearchBaar et al. demonstrated preferential killing of senescent human IMR90 fibroblasts in culture. Huang et al. later reduced senescence-associated cells in expanded healthy-donor human chondrocyte cultures, but treatment did not improve chondrogenic potential in pellet culture. These findings are model-specific and do not establish tissue-wide selectivity in people.
Mouse Aging and Chemotoxicity Models
Preliminary ResearchThe 2017 study reported improvements in fur, activity and renal outcomes in accelerated-aging and naturally aged mouse experiments, and reduced doxorubicin-associated injury. These are preclinical findings; the paper does not establish a universal percentage of senescent-cell clearance across organs or a human anti-aging benefit.
Context-Dependent Effects
Preliminary ResearchSubsequent mouse studies include Leydig-cell dysfunction and bleomycin-induced pulmonary fibrosis. Benefits in these models coexist with a safety counterexample: Born et al. reported worsened pulmonary hemodynamics and endothelial-cell loss with FOXO4-DRI in serotonin-transporter-overexpressing mice. Results in one organ or disease state cannot establish general safety.
Safety & Tolerability
Human safety and pharmacokinetics remain unestablished in the reviewed evidence. The original mouse study reported tolerability under specific conditions, while a later pulmonary-hypertension model reported harm. Neither observation establishes the risk profile in people.
Human data: No human treatment trial was identified in the October 14, 2026 searches. Human-cell evidence includes fibroblasts, chondrocytes, keloid and endothelial cultures; these are preclinical experiments.
- PubMed 28340339
The original mouse study reported tolerability under its tested conditions, not a comprehensive safety assessment.
Animal - PubMed 36515093
FOXO4-DRI worsened pulmonary hemodynamics and endothelial-cell loss in a serotonin-transporter-overexpressing mouse model.
Animal
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. FOXO4-DRI is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| IV / IP (mouse experiments) | 5 mg/kg × 3 | Days 1, 3 and 5 | Baar 2017; later observation is not continuous dosing; no human dose established |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, et al.
Cell (2017)
Original study of a 46-residue D-isoform peptide in human fibroblast cultures and mouse models. Three alternate-day 5 mg/kg injections were used in the illustrated protocols, with intravenous or intraperitoneal administration depending on the experiment. Functional follow-up is not evidence of a multi-week dosing course or a measured plasma half-life.
Senolytic drugs: from discovery to translation
Kirkland JL, Tchkonia T
Journal of Internal Medicine (2020)
Review of senolytic discovery and translation. Its discussion of other senolytics and early clinical trials does not establish human efficacy, selectivity or a dosing regimen for FOXO4-DRI.
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, Lin H
Frontiers in Bioengineering and Biotechnology (2021)
Expanded healthy-donor human chondrocytes: FOXO4-DRI reduced senescence-associated cells but did not improve chondrogenic potential in pellet culture.
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Zhang C, Xie Y, Chen H, et al.
Aging (Albany NY) (2020)
Original aged-mouse study reporting reduced senescent Leydig-cell markers and improved testosterone secretion after three alternate-day injections. Assessment 30 days later does not establish continuous dosing or a human endocrine benefit.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, et al.
Circulation (2023)
FOXO4-DRI worsened pulmonary hemodynamics and endothelial-cell loss in serotonin-transporter-overexpressing mice; other senolytic interventions were tested in additional rodent models.
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Kong YX, Li ZS, Liu YB, et al.
Communications Biology (2025)
Human keloid fibroblast and organ-culture experiments used 25 μM FOXO4-DRI for three days. Organ cultures were followed through day 10; that follow-up is not ten days of continuous treatment or sustained apoptosis.
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Hu Z, Li F, Hu C, et al.
Frontiers in Bioengineering and Biotechnology (2025)
Human endothelial cell experiments and naturally aged/D-galactose-treated mice; animal methods report 5 mg/kg intraperitoneally every two days for one month or four weeks, respectively.
Comparative Research
Explore in-depth research analyses and comparative studies featuring FOXO4-DRI.
Technical Deep Dives
FOXO4-DRI: Senolytic Peptide Mechanism and the p53-FOXO4 Axis
FOXO4-DRI disrupts the FOXO4–p53 interaction and can induce p53 nuclear exclusion and apoptosis in senescent cells. Baar et al. demonstrated preferential killing in human fibroblast cultures and effects in mouse models. Selectivity depends on the model and conditions; it does not establish that all healthy cells are unaffected or that the peptide is safe in humans.
FOXO4-DRI Preclinical Evidence and Translational Challenges: From Mouse Models to Clinical Reality
FOXO4-DRI has been studied in human cell cultures and several mouse models beyond the original 2017 Cell paper. Examples include chondrocytes, keloid fibroblasts, endothelial cells, Leydig-cell dysfunction and pulmonary fibrosis. Results are context-dependent: a pulmonary-hypertension model reported harm. These experiments do not establish human safety, pharmacokinetics or an effective dose; the October 14, 2026 searches identified no human treatment trial.
FOXO4-DRI Research Dosing: Published Animal and Cell Protocols
No safe or effective human FOXO4-DRI dose is established. The original 2017 mouse study used three 5 mg/kg injections on alternate days, followed by observation. Later regimens differ: Hu et al. report 5 mg/kg every two days for a month in a vascular-aging model. Cell-culture concentrations and animal schedules are experimental conditions, not human dosing guidance or measurements of plasma half-life.
FOXO4-DRI Human Trials: Status, Evidence Gaps, and What to Watch (2026)
Searches on October 14, 2026 did not identify a human treatment trial of FOXO4-DRI. ClinicalTrials.gov returned no studies for FOXO4-DRI, FOXO4 DRI or Proxofim; PubMed searches and review of primary reports did not identify a clinical treatment report. Evidence from human cells in culture is preclinical. These searches cannot rule out all unregistered, unpublished or differently named studies worldwide.
FOXO4-DRI Safety and Side Effects: What the Evidence Shows (2026)
Human safety of FOXO4-DRI is not established. The original mouse study reported tolerability under its experimental conditions, but Born et al. later found worsened pulmonary hemodynamics and endothelial-cell loss with FOXO4-DRI in a mouse model. Later animal experiments also include dosing over weeks. These efficacy studies do not provide a comprehensive toxicology program or establish long-term risk in people.
Comparative Clinical Analysis
Epithalon vs FOXO4-DRI: Telomerase Activation vs Senolytic Peptide Comparison for Longevity Research
Epithalon and FOXO4-DRI represent two distinct approaches to cellular anti-aging research. Epithalon, a synthetic tetrapeptide based on pineal gland epithalamin, activates telomerase to maintain or extend telomeres—the protective caps on chromosomes that shorten with age. FOXO4-DRI is a senolytic peptide that selectively induces apoptosis in senescent ('zombie') cells that accumulate with age and secrete harmful inflammatory factors. While Epithalon aims to preserve cellular replicative capacity, FOXO4-DRI eliminates damaged cells that resist normal death. These represent complementary anti-aging strategies: maintaining healthy cells (Epithalon) versus removing harmful ones (FOXO4-DRI).
FOXO4-DRI vs MOTS-c: Anti-Aging Peptide Comparison — Senolytic vs Mitochondrial Approaches
FOXO4-DRI and MOTS-c represent two fundamentally different approaches to biological aging, targeting distinct hallmarks of the aging process. FOXO4-DRI is a senolytic peptide — a D-retro-inverso peptide engineered to selectively eliminate senescent "zombie" cells that accumulate with age and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP). It works by disrupting the FOXO4-p53 protein interaction that protects senescent cells from apoptosis. MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome that improves cellular energy metabolism, insulin sensitivity, and exercise capacity through AMPK activation and metabolic regulation. One approach removes damaged cells; the other improves how remaining cells function. Both are preclinical, but their complementary mechanisms suggest different and potentially synergistic strategies for addressing the biology of aging.
Frequently Asked Questions
What is a D-retro-inverso peptide?
This design reverses a peptide sequence and uses D-amino acids to preserve aspects of side-chain orientation while changing susceptibility to proteases. The original FOXO4-DRI construct is 46 residues long including its cell-penetrating segment. This design does not provide a measured human half-life.
Has FOXO4-DRI been studied in humans?
The October 14, 2026 ClinicalTrials.gov searches for FOXO4-DRI, FOXO4 DRI and Proxofim found no matching study. PubMed searches and primary-paper review did not identify a human treatment trial. Human fibroblast, chondrocyte and endothelial culture studies are preclinical evidence. The search cannot exclude every unregistered or differently named study worldwide.
What dosing protocol was used in the original mouse study?
Baar et al. reported three 5 mg/kg injections on alternate days (days 1, 3 and 5), intravenously in the doxorubicin arm and intraperitoneally in specified aging experiments. Outcomes were observed later, including renal markers at 30 days. It was not a continuous multi-week course.
Do all published studies use only three injections?
No. Later studies use other schedules. Hu et al. report every-two-day dosing for a month or four weeks in mouse vascular-aging experiments. Published animal protocols do not establish a human regimen.
Is FOXO4-DRI safe?
Human safety is not established. The original mouse study reported tolerability under its tested conditions, but Born et al. later found worsened pulmonary hemodynamics in a mouse model. Cell-culture selectivity and short-term mouse observations cannot establish long-term or human safety.
How long do its effects persist after dosing stops?
Some mouse outcomes were measured weeks after a brief course. A later biological effect does not show that intact peptide remained in plasma for that period. Human effect duration and retreatment intervals are not established.
Related Peptides
View allEpithalon
Epithalon is a synthetic tetrapeptide based on the natural peptide Epithalamin produced by the pineal gland. It has been studied for effects on telomerase activity and longevity.
GHK-Cu
GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine, studied in cell and animal models of matrix remodeling and wound repair.
Dihexa
Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.
MOTS-c
MOTS-c is a mitochondria-derived peptide that plays a role in metabolic homeostasis. It is encoded in the mitochondrial genome and affects insulin sensitivity and cellular metabolism.
Thymosin Alpha-1
Thymosin Alpha-1 is a peptide originally isolated from thymic tissue that modulates immune function. It is approved in several countries for immune deficiency conditions and as an adjuvant therapy.
Related Comparisons
Epithalon vs FOXO4-DRI
Epithalon and FOXO4-DRI represent two distinct approaches to cellular anti-aging research. Epithalon, a synthetic tetrapeptide based on pineal gland epithalamin, activates telomerase to maintain or extend telomeres—the protective caps on chromosomes that shorten with age. FOXO4-DRI is a senolytic peptide that selectively induces apoptosis in senescent ('zombie') cells that accumulate with age and secrete harmful inflammatory factors. While Epithalon aims to preserve cellular replicative capacity, FOXO4-DRI eliminates damaged cells that resist normal death. These represent complementary anti-aging strategies: maintaining healthy cells (Epithalon) versus removing harmful ones (FOXO4-DRI).
FOXO4-DRI vs MOTS-c
FOXO4-DRI and MOTS-c represent two fundamentally different approaches to biological aging, targeting distinct hallmarks of the aging process. FOXO4-DRI is a senolytic peptide — a D-retro-inverso peptide engineered to selectively eliminate senescent "zombie" cells that accumulate with age and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP). It works by disrupting the FOXO4-p53 protein interaction that protects senescent cells from apoptosis. MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome that improves cellular energy metabolism, insulin sensitivity, and exercise capacity through AMPK activation and metabolic regulation. One approach removes damaged cells; the other improves how remaining cells function. Both are preclinical, but their complementary mechanisms suggest different and potentially synergistic strategies for addressing the biology of aging.
Related Research
FOXO4-DRI: Senolytic Peptide Mechanism and the p53-FOXO4 Axis
FOXO4-DRI disrupts the FOXO4–p53 interaction and can induce p53 nuclear exclusion and apoptosis in senescent cells. Baar et al. demonstrated preferential killing in human fibroblast cultures and effects in mouse models. Selectivity depends on the model and conditions; it does not establish that all healthy cells are unaffected or that the peptide is safe in humans.
FOXO4-DRI Preclinical Evidence and Translational Challenges: From Mouse Models to Clinical Reality
FOXO4-DRI has been studied in human cell cultures and several mouse models beyond the original 2017 Cell paper. Examples include chondrocytes, keloid fibroblasts, endothelial cells, Leydig-cell dysfunction and pulmonary fibrosis. Results are context-dependent: a pulmonary-hypertension model reported harm. These experiments do not establish human safety, pharmacokinetics or an effective dose; the October 14, 2026 searches identified no human treatment trial.
FOXO4-DRI Research Dosing: Published Animal and Cell Protocols
No safe or effective human FOXO4-DRI dose is established. The original 2017 mouse study used three 5 mg/kg injections on alternate days, followed by observation. Later regimens differ: Hu et al. report 5 mg/kg every two days for a month in a vascular-aging model. Cell-culture concentrations and animal schedules are experimental conditions, not human dosing guidance or measurements of plasma half-life.
FOXO4-DRI Human Trials: Status, Evidence Gaps, and What to Watch (2026)
Searches on October 14, 2026 did not identify a human treatment trial of FOXO4-DRI. ClinicalTrials.gov returned no studies for FOXO4-DRI, FOXO4 DRI or Proxofim; PubMed searches and review of primary reports did not identify a clinical treatment report. Evidence from human cells in culture is preclinical. These searches cannot rule out all unregistered, unpublished or differently named studies worldwide.
FOXO4-DRI Safety and Side Effects: What the Evidence Shows (2026)
Human safety of FOXO4-DRI is not established. The original mouse study reported tolerability under its experimental conditions, but Born et al. later found worsened pulmonary hemodynamics and endothelial-cell loss with FOXO4-DRI in a mouse model. Later animal experiments also include dosing over weeks. These efficacy studies do not provide a comprehensive toxicology program or establish long-term risk in people.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.